Zinmyleo (trilaciclib)
- Region
- 🇪🇺 EU
- Active substance
- trilaciclib
- Company
- Pharmacosmos A/S
- Status
- Application withdrawn
- Therapeutic area
- Small Cell Lung Carcinoma
- Application
- EMEA/H/C/006709
- ATC
- V03AF12
- Official record
- www.ema.europa.eu
Indication
Prevention of chemotherapy-induced myelosuppression when administered prior to platinum/etoposide- or topotecan-containing regimens for extensive-stage small cell lung cancer (ES-SCLC).
Regulatory milestones
Wed 22 Jul 2026🇪🇺 Application withdrawn (EU)
Zinmyleo (trilaciclib): EU application withdrawn
Follow Zinmyleo
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.